Aarey Drugs & Pharmaceuticals Limited
Aarey Drugs & Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients, intermediates, and specialty chemicals for various industrial applications in India. The company offers intermediates, including mono methyl urea, di methyl urea, ortho para nitro anisole, 2-bromomethyl-1,3-dioxolane, and uracil. It also provides active pharmaceutical ingredients, such as metformin HCl… Read more
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) - Total Assets
Latest total assets as of September 2025: ₹2.94 Billion INR
Based on the latest financial reports, Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) holds total assets worth ₹2.94 Billion INR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Aarey Drugs & Pharmaceuticals Limited - Total Assets Trend (2009–2025)
This chart illustrates how Aarey Drugs & Pharmaceuticals Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Aarey Drugs & Pharmaceuticals Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Aarey Drugs & Pharmaceuticals Limited's total assets of ₹2.94 Billion consist of 89.5% current assets and 10.5% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹0.00 | 0.6% |
| Accounts Receivable | ₹1.60 Billion | 67.0% |
| Inventory | ₹454.80 Million | 19.1% |
| Property, Plant & Equipment | ₹0.00 | 0.0% |
| Intangible Assets | ₹0.00 | 0.0% |
| Goodwill | ₹0.00 | 0.0% |
Asset Composition Trend (2009–2025)
This chart illustrates how Aarey Drugs & Pharmaceuticals Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aarey Drugs & Pharmaceuticals Limited's current assets represent 89.5% of total assets in 2025, an increase from 75.2% in 2009.
- Cash Position: Cash and equivalents constituted 0.6% of total assets in 2025, down from 2.6% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2009.
- Asset Diversification: The largest asset category is accounts receivable at 67.0% of total assets.
Aarey Drugs & Pharmaceuticals Limited Competitors by Total Assets
Key competitors of Aarey Drugs & Pharmaceuticals Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM
|
USA | $41.43 Million |
|
High Sierra Technologies Inc
PINK:HSTI
|
USA | $10.70K |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
Aarey Drugs & Pharmaceuticals Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Aarey Drugs & Pharmaceuticals Limited generates 1.99x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Aarey Drugs & Pharmaceuticals Limited generates $ 1.69 in net profit.
Aarey Drugs & Pharmaceuticals Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.79 | 1.82 | 4.64 |
| Quick Ratio | 1.52 | 1.60 | 3.72 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₹1.14 Billion | ₹ 1.13 Billion | ₹ 844.78 Million |
Aarey Drugs & Pharmaceuticals Limited - Advanced Valuation Insights
This section examines the relationship between Aarey Drugs & Pharmaceuticals Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.27 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -21.4% |
| Total Assets | ₹2.38 Billion |
| Market Capitalization | $12.11 Million USD |
Valuation Analysis
Below Book Valuation: The market values Aarey Drugs & Pharmaceuticals Limited's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Aarey Drugs & Pharmaceuticals Limited's assets decreased by 21.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Aarey Drugs & Pharmaceuticals Limited (2009–2025)
The table below shows the annual total assets of Aarey Drugs & Pharmaceuticals Limited from 2009 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | ₹2.38 Billion | -21.44% |
| 2024-03-31 | ₹3.03 Billion | +4.11% |
| 2023-03-31 | ₹2.91 Billion | +18.83% |
| 2022-03-31 | ₹2.45 Billion | +5.21% |
| 2021-03-31 | ₹2.33 Billion | +20.07% |
| 2020-03-31 | ₹1.94 Billion | +33.19% |
| 2019-03-31 | ₹1.46 Billion | -14.18% |
| 2018-03-31 | ₹1.70 Billion | +18.51% |
| 2017-03-31 | ₹1.43 Billion | +14.62% |
| 2016-03-31 | ₹1.25 Billion | +8.74% |
| 2015-03-31 | ₹1.15 Billion | +7.54% |
| 2014-03-31 | ₹1.07 Billion | -0.21% |
| 2013-03-31 | ₹1.07 Billion | +23.35% |
| 2012-03-31 | ₹868.36 Million | +103.54% |
| 2011-03-31 | ₹426.64 Million | +63.33% |
| 2010-03-31 | ₹261.20 Million | +69.57% |
| 2009-03-31 | ₹154.04 Million | -- |